Hotstocked Newsletters

Promoted Companies

PROMOTION HISTORY
SORT BY:

Cell Therapeutics, Inc. (CTIC)

Total paid for Promotions this month: $0
E-mails this Month: 1
Estimated Volume Generated: $0
Research Report on CTIC: Click to see
* The information presented is based on information for Feb , 2016
GPSMillionaires,  Heading into the Lunch hour we're going to issue a official sell alert with $CTIC$... Holding through the volatile swing is going to prove to be not in our  favor as a Legal Investigation of $CTIC$ has been announced. This being an impossible situation that couldn't be seen will only further to damage the share price to the stock. Details Below:    INVESTOR ALERT: Investigation ...read more
Promoter: Golden Penny Stock Millionaires Lab Head Quarters Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
CTIC Unknown compensation UNKNOWN
Max Profit: 14.38 % Gain at close: Pending
Let's go over a few trades as we head toward the opening bell this trading day. FNMA - has continued its bullish push as we are sitting at $2.42 a  share. We entered this trade at $2.33 a share and we need to  break price resistance of $2.42 which was touched in yesterday's trading session. Let's look to hold our position as we expect some sideways price action to take place... Although a steady ...read more
Promoter: Golden Penny Stock Millionaires Lab Head Quarters Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
CTIC Unknown compensation UNKNOWN
Max Profit: 3.13 % Gain at close: 2.50 %
Radar Signals: Positive Final Guidance On Its Novel Aza-Anthracenedione (Mailing list information, including unsubscription instructions, is located at the end of this message.)   Cell Therapeutics, Inc. (CTIC)   Non-Hodgkin lymphoma (sometimes called NHL, or just lymphoma) is a cancer that starts in cells called lymphocytes, which are part of the body’s immune system.   Non-Hodgkin lymphomas (NHL) can occur at any age and are often ...read more
Promoter: Crweselect.com Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
CTIC Unknown compensation UNKNOWN
Max Profit: 0.49 % Gain at close: -3.92 %
Biopharma Signals Could Attract Radars Attention (Mailing list information, including unsubscription instructions, is located at the end of this message.)   Alimera Sciences, Inc. (ALIM)   ALIM reported that it has obtained commitments from certain non-affiliated institutional investors to purchase approximately $37.5 million of its common stock in a private placement.   According to ALIM, this financing will provide the company ...read more
Promoter: pennyomega.com Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
CTIC Unknown compensation UNKNOWN
Max Profit: 0.49 % Gain at close: -3.92 %
Biopharma Signals Could Attract Radars Attention     Alimera Sciences, Inc. (ALIM)   ALIM reported that it has obtained commitments from certain non-affiliated institutional investors to purchase approximately $37.5 million of its common stock in a private placement.   According to ALIM, this financing will provide the company with working capital to support its continued commercialization of ILUVIEN(R) in Europe and the ongoing ...read more
Promoter: penny to buck Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
CTIC Unknown compensation UNKNOWN
Max Profit: 0.49 % Gain at close: -3.92 %
It Gets $5M Milestone Payment, Eligible to Receive Up to an Additional $95M in Payments (Mailing list information, including unsubscription instructions, is located at the end of this message.) Cell Therapeutics, Inc. (CTIC)   CTIC reported that it has received a $5 million milestone payment from Teva Pharmaceutical Industries Ltd. related to the achievement of a sales milestone for TRISENOXR) (arsenic trioxide).   TRISENOX was acquired ...read more
Promoter: penny to buck Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
CTIC Unknown compensation UNKNOWN
Max Profit: 0.49 % Gain at close: -3.92 %
Cell Therapeutics CTIC Gets Financing – Phase 3 Clinical Trials (Mailing list information, including unsubscription instructions, is located at the end of this message.) Cell Therapeutics CTIC has been makings gains lately on speculation of their latest financing to fund phase 3 clinical trials for PIXUVRI® (pixantrone). CTIC closed at $1.46 today with 5,506,422 shares traded. The company raised $14.8 M (headline below). CTI ...read more
Promoter: pennyomega.com Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
CTIC Unknown compensation UNKNOWN
Max Profit: 0.68 % Gain at close: -5.48 %
Cell Therapeutics CTIC Gets Financing – Phase 3 Clinical Trials (Mailing list information, including unsubscription instructions, is located at the end of this message.) Cell Therapeutics CTIC has been makings gains lately on speculation of their latest financing to fund phase 3 clinical trials for PIXUVRI® (pixantrone). CTIC closed at $1.46 today with 5,506,422 shares traded. The company raised $14.8 M (headline below). CTI ...read more
Promoter: penny to buck Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
CTIC Unknown compensation UNKNOWN
Max Profit: 0.68 % Gain at close: -5.48 %
    Openwave Systems Inc. (Nasdaq:OPWV) announced this month that Openwave Media Optimizer, an intelligent, content- and context-aware media optimization solution that works to automatically trigger optimization when the network reaches pre-determined thresholds, has won the Special Editor Recognition - Best Network Management and Optimization Solution award in this year’s Telecom Asia Readers’ Choice Awards. “Openwave ...read more
Promoter: Double in stocks Paying Party: No Third Party
Stocks covered: Compensation: Avg $ Volume for Period:
OPWV Unknown compensation UNKNOWN
Max Profit: Pending Gain at close: Pending
CTIC Unknown compensation UNKNOWN
Max Profit: Pending Gain at close: Pending
Video not found or You must install the Flash Plugin for your Browser in order to view this movie